Skip to main content
. 2019 Feb 27;17(2):e05598. doi: 10.2903/j.efsa.2019.5598

Figure 55.

Figure 55

Trends in ciprofloxacin, erythromycin and tetracycline resistance in Campylobacter coli from humans in reporting countries, 2013–2017

  • Statistically significant increasing trends over 3–5 years, as tested by logistic regression (p ≤ 0.05), were observed for ciprofloxacin in Estonia, Finland, Slovakia and Slovenia (↑), for tetracycline in France, the Netherlands, Slovakia and Slovenia (↑). Statistically significant decreasing trends were observed for ciprofloxacin and erythromycin in France (↓). Only countries reporting at least 10 isolates per year were included in the analysis.